Nervous Disorder TRIZ Cases

Framework-region amino acid substitutions raise TRBV9 antibody humanization while preserving affinity and solubility for pathogenic T-cell targeting.

Molecular sequence changes and PEG attachment extend calcitonin half-life, reducing injection frequency while maintaining therapeutic effect.

Polar lipid-rich Nannochloropsis oil boosts low-dose CBD bioavailability to improve sleep quality without the sedation seen with high-dose CBD.

Targeted Fc amino acid substitutions strengthen FcRn binding at pH 6.0 while preserving release at pH 7.4 to extend IgG serum half-life.

A PEG ester solubilizer and antioxidant keep capsaicin soluble and oxidation-resistant in aqueous injectable formulations during storage.

Guide RNA directs Cas9 to the SCN9A gene for precise, reproducible editing that reduces pain-related gene expression in one treatment.

Novel cereblon-binding small molecules improve substrate specificity and tumor cell death while reducing adverse effects of existing modulators.

Low-temperature trichome separation and staged alcohol extraction raise CBD while keeping THC below 0.5% for refractory epilepsy use.

An RE1-binding transcription factor vector enables glial-to-neuron conversion in vivo, overcoming poor efficacy of in vitro screened factors.

Selective compounds inhibit mTORC2 to reduce Aβ production, promote autophagy, and help prevent neuronal death in neurodegeneration.

Truncated calcitonin analogues with targeted amino acid changes improve neutral pH stability and extend half-life to reduce injection frequency.

Lowering brain oxygen through hemoglobin left-shifting or anemia helps counter mitochondrial dysfunction and improve neurological function.

Marker-based selection of Corin- and Lrtm1-positive progenitors improves survival, consistency, and cost in Parkinson's cell production.

Antibodies engineered to bind alpha-synuclein fibrils and monomers can block aggregation spread between neurons and reduce Lewy body pathology.

A tick-derived polypeptide reduces neuroinflammation and neuronal death after brain hemorrhage without increasing hemorrhage volume or edema.

Engineered anti-TREM2 antibodies promote extracellular-domain cleavage to consistently raise soluble TREM2 and enhance microglial phagocytosis.

VH4 antibodies with AGS mutations help target pathologic immune processes to reduce demyelination, inflammation, and axonal injury.

Combining adrenergic and RAAS-targeting agents helps treat multifactorial affective disorders by balancing cerebral blood flow and stress responses.

A buffered aqueous vigabatrin oral solution keeps pH at 5-8 to balance stability, solubility, taste, and patient compliance.

Codon-optimized PSEN1 delivered by AAV, exosomes, or lipid nanoparticles restores γ-secretase activity in Alzheimer's disease.

Low-dose intra-arterial ethyl alcohol opens the BBB uniformly for about 120 minutes, enabling targeted brain delivery with fewer adverse effects.

Targeting ApoE with therapeutic antibodies helps clear Aβ plaques, lowering plaque burden in Alzheimer's disease and cerebral amyloid angiopathy.

HSPC transplantation generates healthy microglia that reduce amyloid plaques and neuroinflammation while preserving memory in Alzheimer's models.

Genetic analysis identifies SIM2 variant carriers for targeted agonist therapy aimed at slowing or preventing Parkinson's disease progression.

Amphiphilic small molecules balance BBB permeability with selective Aβ oligomer binding to reduce neurotoxicity and support early AD imaging.

Gut microbiota restoration with antibiotics, bowel cleanse, and fecal transfer reduced core ASD severity and GI symptoms.

A rotational cam and spring-driven piston deliver precise transdermal bolus doses from a compact reservoir while reducing size, cost, and side effects.

A porous PLC wound film releases local analgesic for days, reducing painful dressing changes and limiting opioid use.

Combining marker-defined Schwann cell precursors or Schwann cells with NK cells improves neurotrophic secretion and nervous system regeneration.

Targeting TACE/ADAM17 with alpha1-antitrypsin helps reduce inflammation and oxidative stress while rescuing Schwann cells in CIDP.

Multi-stage extraction, winterization, and fractional distillation raise beta-caryophyllene yield from black pepper for terpene-rich nutraceutical extracts.

Nitric oxide-releasing MDA and MDMA prodrugs aim to improve depression and PTSD treatment by preserving therapeutic effects with better safety.

Specific fragrance compounds improve sleep duration, REM and deep sleep through olfactory pathways without invasive drug-based intervention.

An AAV vector delivers the ChAT gene to the CNS to restore cholinergic function and slow Alzheimer's progression beyond symptom relief.

Humanized anti-Tau antibodies improve brain delivery and Tau clearance while limiting edema and microhemorrhage at higher doses.

Glial-enriched progenitor cells are delivered near the infarct core to support myelin repair, cell integration, and recovery after white matter stroke.

Small molecules targeting the TLX ligand-binding domain tune coactivator binding and receptor stability to promote neurogenesis and treat cancer.

Short FPR-targeting peptide analogues extend in vivo half-life while modulating neutrophils and inflammatory cells to help control multiple sclerosis.

Anti-pro/latent myostatin antibodies address metabolic dysregulation while preserving lean muscle, reducing fat mass, and improving metabolic rate.

3-SPA blocks toxic Aβ42 oligomer formation while avoiding plaque-targeting antibody risks such as ARIA-E in Alzheimer's treatment.

Disrupting serine dehydratase raises serine while lowering deoxyceramide, offering a tissue-level alternative to restrictive dietary control.

Novel GPR17-modulating sulfonamides promote oligodendrocyte differentiation, enhance remyelination, and help protect axons.

Targeting Galectin-3 with antibodies reduces neuroinflammation and neural hyper-excitability in refractory epilepsy and related disorders.

A universal RNA-guided nuclease paired with modular guide RNA enables sequence-specific genome editing with lower design cost and complexity.

A cyclic peptide derivative uses tailored ring and substituent structure to selectively enhance astrocyte proliferation in nervous system cells.

Pridopidine targets ALS progression by restoring axonal transport, reducing mutant SOD1 aggregates, and helping preserve muscle and respiratory function.

Combining TLR4/MD2 pathway and EGFR inhibitors helps suppress tumor growth while delaying resistance in EGFR-resistant and wild-type cancers.

Formula (A) compounds use tailored aryl, alkynyl, and heteroaryl groups to selectively inhibit AKR1C3 with better pharmacokinetics and fewer side-effects.

Targeting the Sestrin-GATOR2 interface enables selective mTORC1 modulation for treating diseases linked to pathway dysregulation.

GLP-1 receptor agonists such as semaglutide are used to lower dementia risk and support cognitive function in patients with metabolic syndrome.

Engineered antibodies target Aβ(20-42) globulomers to inhibit activity without inducing microhemorrhages.

Hydroxy-triglycerides resist metabolic breakdown to treat diseases by modifying membrane lipids instead of serving as fuel.

Oral administration of a specific galactooligosaccharide composition reduces cortisol secretion and improves cognitive impairment in neuropsychiatric disorders.

Segmenting steroid rings with local quality modifications boosts anesthetic potency while clarifying structural features driving receptor activity.

Iodinated polyether compounds self-assemble into hydrophobic domains to enhance medical imaging visibility.

Sobetirome addresses Pitt-Hopkins Syndrome myelination deficits by promoting oligodendrocyte maturation and rescuing electrophysiological abnormalities.

Human antibodies bind the N-terminal region of protease-activated receptor-2 to block activating cleavage, inhibiting signaling for pain and inflammation.

COMT genotyping stratifies patients by Val158Met locus to optimize proline levels, addressing persistent negative symptoms in schizophrenia therapy.

Novel GIP/GLP-1 dual agonist peptides reduce beta-amyloid plaque load and protect synapses in animal models.

Replacing DH2 domains in polyketide synthases boosts polyunsaturated fatty acid yields while resolving mixed-chain contamination issues.

Systemic SCO-Spondin peptides reduce tau protein accumulation, addressing limited treatment options for tauopathies.

RCSGI targets synaptic connections to modulate norepinephrine levels, resolving treatment resistance in PTSD and hot flash patients.

Personalized cannabinoid formulations match patient genotypes via adjusted CBD:THC ratios and terpene profiles to resolve inconsistent therapeutic efficacy.

Local injection around sensory nerves blocks neuroexcitatory chemical migration, preventing progressive motor neuron death in amyotrophic lateral sclerosis.

Covalent linker attachment extends in vivo duration of action and improves tolerability against rapid biodegradation.

Modified GLP-1 peptides extend therapeutic duration through specific amino acid substitutions and fatty acid amide anchors.

SCD1 antagonists disrupt FGFR3-regulated lipogenic pathways to inhibit cancer cell proliferation, resolving limited targeting of crucial signaling mechanisms.

A method using enucleated 2-cell embryos to receive differentiated cell nuclei for generating pluripotent stem cells.

Annexin 1 mimetics physically associate with the NF-kB dimer to prevent DNA binding, reducing inflammation and cancer cell proliferation.

A binding molecule targets the TREM2 ectodomain to inhibit cleavage and stabilize surface receptors.

Monoclonal antibodies target isoaspartate residues on transthyretin proteins to enable phagocytic uptake of amyloid fibrils.

Porous ethylcellulose films control gamma-hydroxybutyrate diffusion to prevent dose dumping from hygroscopic high-solubility drugs.

Specific amino acid and organic acid composition enhances mitochondrial biogenesis.

Local precursor conversion maintains bone density while reducing cancer risk from systemic hormone exposure.

Phospholipid microspheres encapsulate biphenol to overcome water insolubility while antioxidants prevent oxidation.

Caninized anti-NGF antibodies bind canine nerve growth factor to inhibit pain signaling pathways in veterinary treatments.

PEGylated aptamers reduce immune response while maintaining therapeutic efficacy against complement disorders.

Multispecific antibodies bind transferrin receptors to cross the blood-brain barrier, targeting amyloid-beta and tau pathology in Alzheimer's disease.

N-terminal GIP peptides modulate synaptic long-term potentiation to treat cognitive deficits from neurodegeneration or trauma.

A pharmaceutical composition containing prickly pear extract, reduced L-Glutathione, and N-Acetyl-L-Cysteine improves alcohol metabolism.

A modified tumor antigen polypeptide enhances MHC class II binding and protease resistance to promote Th cell activation.

TCAP-1 peptide counteracts corticotrophin releasing hormone effects, reducing opioid withdrawal stress responses and drug-seeking behavior.

N-terminal truncation of GDNF reduces heparin binding to improve brain delivery while maintaining neuroprotective receptor activity.

Codon-optimized reduced-size ATP7A nucleic acids fit limited adeno-associated virus vector capacity while maintaining copper transport function.

A terpolymer-coated filter removes abnormal prion proteins and leukocytes from blood products, eliminating separate processing steps.

Specific antibodies bind mature TGF Beta 1 to neutralize activity and slow chronic renal disease progression.

Antisense oligonucleotides inhibit LRP-1 expression to reverse myelin-associated protein inhibition and enhance axonal regeneration.

A composite nerve guide merges a decellularized allograft scaffold with a polymer conduit containing double-walled microspheres to deliver neurotrophic factors.

A chimeric antigen binding protein combines human variable regions with non-human constant regions to enhance structural integrity.

A cross-linked high amylose starch matrix controls drug release kinetics through diffusion and degradation mechanisms.

Differentiated astrocytes secrete GDNF to protect dopaminergic neurons, resolving cell survival challenges in Parkinson's disease therapy.

Periodic alemtuzumab cycles reduce MS relapse frequency, minimizing autoimmune complications compared to continuous high-dose therapy.

Introducing reactive CD4 positive T cells into stressed non-human animals to model cerebrovascular inflammation.

A nasal composition uses porous and nonporous silicon dioxide to bind airborne contaminants at the mucosal surface.

Poloxamer surfactant stabilizes cenobamate suspension, resolving pediatric administration and stability trade-offs.

Segmented carrier molecules guide drugs to target tissues via selective uptake, reducing toxicity to normal tissues while maintaining therapeutic efficacy.

Segmenting the molecule into three modules merges binding and recruitment functions, enabling proteasomal degradation of pathogenic proteins.